Etostar 90 Tablet: Each film coated tablet contains Etoricoxib INN 90 mg.
Etostar 120 Tablet: Each film coated tablet contains Etoricoxib INN 120 mg.
It is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. It is a potent, orally active, highly selective cyclooxygenase-2 (COX-2) inhibitor within and above the clinical dose range. COX-2 has been shown to be primarily responsible for the synthesis of prostanoïd mediators of pain, inflammation, and fever. Selective inhibition of COX-2 by Etoricoxib decreases these clinical signs and symptoms with decreased GI toxicity and without effects on platelet function.
Etoricoxib is indicated for the relief of pain and inflammation in:
a) Route of administration: Oral.
Adult and adolescent over 16 years:
a) With Medicine: The metabolism of Etoricoxib can be increased when combined with Abatacept. The serum concentration of Etoricoxib can be increased when it is combined with Abiraterone. The metabolism of Acalabrutinib can be decreased when combined with Etoricoxib. The risk or severity of adverse effects can be increased when Etoricoxib is combined with Aceclofenac. The risk or severity of adverse effects can be increased when Etoricoxib is combined with Acemetacin.
b) With Food and Other: Take with or without food. The absorption is unaffected by the food.
Overdose:
No over dose of Etoricoxib were reported during clinical trials. In clinical studies, administration of a single dose of Etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity.
Pregnancy: Etoricoxib tablets must not be taken during pregnancy. It should be used during upto second trimesters of pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk.
It is not recommended for children and adolescents. It can be given adults and adolescents over 16 years.
In patients with advanced renal disease, treatment with it is not recommended. Clinical experience in patients with estimated creatinine clearance of <30 ml/min is very limited. If therapy with it must be initiated in such patients, close monitoring of the patient’s renal function is advisable. Caution should be used when initiating treatment with it in patients with considerable dehydration. It is advisable to reduce patients prior to starting therapy with it. The possibility of fluid retention, oedema or hypertension should be taken into consideration when it is used in patients with pre-existing oedema, hypertension, or heart failure. Independent of treatment, patients with a prior history of GI perforation, ulcers and bleeding (PUB) and patients greater than 65 years of age are known to be at a higher risk for a PUB. A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be evaluated for persistently abnormal liver function tests. If persistently abnormal liver function tests (three times the upper limit of normal) are detected, it should be discontinued. It should be used with caution in patients who have previously experienced acute asthmatic attacks, urticaria or rhinitis, which were precipitated by salicylates or non-selective cyclooxygenase inhibitors. It may mask fever, which is a sign of infection. The physician should be aware of this when using it in patients being treated for infection.
Store below 30°C. Protect from light and moisture. Keep all medicines out of reach of children.